Outline Flashcards
1
Q
- General considerations of antimicrobial therapy. Disinfectants and antiseptics
A
A. General considerations of antimicrobial therapy:
- Definitions
- Mechanisms of action
- Characteristics of antibiotic therapy
- Types of therapies
- The basic conditions of an effective therapy
- Post-antibiotic effect
- Relationship of the AUC and MIC
- MBC
- MIC
- Cmax/MIC - Concentration-dependent antibacterial activity
- T > MIC - Time-dependent antibacterial activity
- AUC/MIC
- Relationship of the AUC and MIC
- Combination of antimicrobial agents
- Indication of prophylactic treatment
- Surgical prophylaxis
- Non-surgical prophylaxis
- Antibacterial spectrum
- Narrow
- Extended
- Broad
- Complications of antibiotic therapy
- Hypersensitivity
- Direct toxicity
- Superinfection
B. Disinfectants and antiseptics:
- Features
- Mechanisms of action of disinfectants
- General features of disinfectants
-
Alcohols:
- Types
- Features
-
Aldehydes:
- Types
- Features
-
Phenol and derivatives:
- Phenol
- Phenol-derived agents
- Acids
- Halogens
- Oxidizing agents:
- Heavy metals
- Quaternary ammonium compounds (detergents and soaps)
- Physical antimicrobial
2
Q
- Antimycobacterial drugs
A
A. General:
- Mycobacteria and species
B. Tuberculosis:
- TB therapy protocols
- Standard
- Actively growing bacteria
- Dormant bacteria
- Strategies for drug resistance
-
1st line drugs:
- Rifampin
- Isoniazide
- Pyrazinamide
- Ethambutol
- Streptomycin
-
2nd line drugs:
- Ethionamide
- Cycloserine
- Paraminosalicylic acid (PAS)
- Kinamycin
- Amikacin
- Capreomycin
- Fluoroquinolones
- Rifabutin
- Linezolid
C. Leprosy:
- Drugs
- Dapsone
- Rifampine
- Clofamazine
3
Q
- Antiprotozoal and antihelminthic drugs.
A
A. Antiprotozoal agents:
-
Malaria disease
- Life cycle of plasmodium
- Classification of drugs
- Drugs
- Chloroquine
- Quinine, quinidine
- Mefloquine
- Primaquine
- Halofantrine
- Lumefantrine
- Pyrimethamine + sulfadoxine
- Malaron = Atovaquone + proguanil
- Arteminisin
- Antibiotics (tetracyclines, Clindamycin, Azithromycin)
-
Amebiasis
- Disease
- Drugs
- Idoquinol
- Diloxanid fuorat
- Nitroimidazoles (metronidazole, tinidazole)
- Paromomycin
-
Giardiasis:
- Disease
- 1st line drugs:
- Nitroimidazoles
- Nitazoxanid
- 2nd line drugs
- Paromomycin
- Nitrofuran
- Quinacrin
-
Trichomoniasis:
- Disease
- Drugs
- Nitroimidazoles
-
Toxoplasmosis:
- Disease
- 1st line drugs
- Spiramycine
- Sulfamethoxazol + Trimethoprim
- Pyrimethamine + clindamycin + folinic acid
- 2nd line
- Pyrimethamine + sulfadiazine + folinic acid
-
Pneumocystis infection:
- Disease
- 1st line drugs
- Sulfamethoxazole + trimethoprim
- 2nd line drugs
- Pentamidine or clindamycin + primaquine or atovaquone
-
Leishmaniasis:
- Disease
- Visceral leishmaniasis drugs
- Amphotericin B
- Miltefosine
- Pentamidine
- Cutaneous leismaniasis drugs
- Pentamidine
- Ketoconazole
- Mucocutaneous leishmaniasis drugs
- Sodium stibugluconate
- Meglumin antimoniat
-
Trypanosomiasis:
- Disease
- African trypanosomiasis drugs
- Pentamidine
- Suramin
- Melarsoprol
- Eflornithine
- South American trypanosomiasis drugs
- Nifurtimox
- Benznidazole
B. Antihelminthic agents:
- Helminths
- Drug targets
- Drugs
- Benzimidazoles: Albendazole, Mebendazole, Tiabendazole
- Ivermectin
- Levamisol
- Pyrantel pamoate
- Praziquantel
- Niclosamide
- Bithionol
4
Q
- Antifungal agents
A
- Types of fungi
- Systemic fungal infections
- Classifications of antifungal drugs
- Based on mechanism
- Based on structure
A. Systemic antifungal drugs for systemic infections:
-
Polyenes
- Drugs
- Amphotericin B
- Mechanism of action
- Spectrum
- Pharmacokinetics
- Clinical use
- Adverse effects
- Drugs
-
Antimetabolites
- Drugs
- Flucytosine
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
- Drugs
-
Azoles
- Drugs
- Imidazoles
- Clotrimazole
- Ketoconazole
- Triazoles
- 1st generation: fluconazole, itraconazole
- 2nd generation: Voriconazole, posaconazole
- Imidazoles
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
- Drugs
-
Echinocandins
- Drugs
- Capsofungin
- Micafungin
- Anidulafungin
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
- Drugs
B. Systemic antifungals for mucocutaneous infections:
-
Terbinafin
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Griesofulvin
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
C. Topical antifungal drugs:
-
Nystatin
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
- Others:
- Allylamines
- Terbinafine
- Naftifin
- Amorolfine
- Ciclopirox
- Azoles
- Allylamines
5
Q
- Agents to treat Herpes simplex (HSV), varicella-zoster (VZV) virus, cytomegalovirus (CMV) and respiratory syncytial virus (RSV) infection. Anti-influenza agents
A
A. Viruses:
- Intro
- Target of antiviral agents
- Resistance of antiviral agents
B. Treatment of herpes viruses:
-
Agents for HSV-1, HSV-2, VZV:
-
Acyclovir
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Resistance
- Adverse effects
-
Valacyclovir
- Mechanism of action
- Pharmacokinetics
- Clinical use
-
Penciclovir
- Mechanism of action
- Administration
- Clinical use
- Adverse effects
-
Famciclovir
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
- Vidarabine (Trifluoruridine, idoxuridine)
- Brivudin
- Docosanol
- Trifuridine
-
Acyclovir
-
Agents for CMV:
-
Ganciclovir and valganciclovir
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Cidofivir
- Mechanism of action
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Foscarnet
- Mechanism of action
- Pharmacokinetics
- Spectrum
- Clinical use
- Adverse effects
-
Ganciclovir and valganciclovir
C. Respiratory syncytial virus (RSV) infection:
-
Ribavirin
- Mechanism of action
- Pharmacokinetics
- Spectrum
- Clinical uses
- Side effects
- Palivisumab
D. Anti-influenza agents:
-
Neuraminidase inhibitors
- Zanamivir, Oseltamivir
- Mechanism of action
- Pharmacokinetics
- Clinical uses
- Adverse effects
- Zanamivir, Oseltamivir
-
Amantadine
- Mechanism of action
- Pharmacokinetics
- Clinical uses
- Side effects
6
Q
- Antiretroviral agents
A
A. HAART therapy:
- Overview
- Indications
-
Nucleoside reverse transcriptase inhibitors (NRTIs)
- Mechanism
- Drugs
- Thymidine analogs
- Zidovudine
- Stavudine
- Cytidine analogs
- Lamivudine
- Emtricitabine
- Purine analogs
- Didanosine
- Abacavir
- Tenofovir
- Thymidine analogs
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- Mechanism of action
- Drugs
- 1st generation
- Nevirapin
- Efavirenz
- Delavirdine
- 2nd generation
- Etravirin
- Rilpivirin
- 1st generation
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Protease inhibitors
- Mechanism of action
- Drugs
- Ritonavir
- Tipranavir
- Lopinavir
- Darunavir
- Atanavir
- …
- Pharmacokinetics
- Clinical uses
- Side effects
-
Inegrase inhibitors
- Mechanism of action
- Administration
- Adverse effects
- Drugs
- Raltegravir
- Elvitegravir
- Dolutegravir
-
Integrase inhibitors
- Mechanism of action
- Administration
- Adverse effects
- Drugs
- Raltegravir
- Elvitegravir
- Dolutegravir
-
Entry inhibitors
- Enfuvirtide
- Sifuvirtide
- Ibalizumab
- Maraviroc
-
Maturation inhibitor
- Bevirimat
7
Q
- Agents against hepatitis viruses
A
- Interferons:
- IFN-alpha2a, IFN-alpha2b:
-
HBV treatment:
-
NRTIs
- Lamivudine
- Adefovir
- Entecavir
- Tenofovir
- Telbivudine
-
NRTIs
-
HCV treament:
- INF alpha
- Ribavarin
- NS3 protease inhibitor - e.g. Simeprevir
- NS5b RNA polymerase inhibitor - Sofosbuvir
- Non-nucleoside NS5b RNA polymerase inhibitor - Dasabuvir
- NS5A transcription complex inhibitors - e.g. Daclatasvir
8
Q
- Penicillins
A
- Mechanism of action
- Mechanism of resistance
- General considerations
- Pharmacokinetics
- Adverse effects
-
Basic penicillins
-
Drugs
- Penicillin G
- Penicillin V
- Penamecillin
- Spectrum
-
Drugs
-
Anti-staphylococcal penicillins
- Drugs
- Methicillin
- Nafcillin
- Oxacillin
- Cloxacillin
- Dicloxacillin
- Flucloxacillin
- Spectrum
- Drugs
-
Aminopenicillins
- Drugs
- Ampicillin
- Amoxicillin
- Spectrum
- Pharmacokinetics
- Indications
- Adverse effects
- Drugs
-
Antipseudomonal penicillins
- Drugs
- Piperacillin
- Ticarcillin
- Indications
- Drugs
9
Q
- Cephalosporins
A
- Classification scheme
- Common characteristics
- Mechanism of action and resitance
- Pharmacokinetics
- Adverse effects
-
1st generation
- Drugs
- Parenteral
- Cefalothin
- Cefazolin
- Oral
- Cephalexin
- Cephradine
- Cephadroxil
- Parenteral
- Spectrum
- Pharmacokinetics
- Clinical use
- Drugs
-
2nd generation
- Drugs
- Parenteral
- Cefoxitin
- Cefotetan
- Cefonicid
- Cefamandol
- Cefuroxime
- Oral
- Cefaclor
- Fefuroxime axetil
- Cefprozil
- Parenteral
- Spectrum
- Pharmacokinetics
- Clinical use
- Drugs
-
3rd generation
- Drugs
- Parenteral
- Cefotaxime
- Cefoperazone
- Ceftriaxone
- Ceftazidine
- Ceftizoxime
- Oral
- Cefixim
- Ceftibuten
- Parenteral
- Spectrum
- Indications
- Pharmacokinetics
- Drugs
-
4th generation
- Cefepim
- Ceftolozon (+ tazobactam)
-
5th generation
- Ceftarolin fosamil
10
Q
- Carbapenems. Monobactams. Beta-lactamase inhibitors
A
A. Carbapenems:
- 1st generation
- Ertapenem
- 2nd generation
- Imipenem
- Meropenem
- Doripenem
- Overview
- Spectrum
- Mechanism of resistance
- Pharmacokinetics
- Adverse effects
B. Monobactams:
- Drug
- Aztreonam
- Spectrum
- Clinical use
C. Beta-lactamase inhibitors:
- Clavulanic acid, sulbactam, tazobactam
- Combinations
- Amoxicilline-clavulanic acid
- Ampicillin-sulbactam
- Piperacillin-tazobactam
11
Q
- Chloramphenicol. Polymyxins. Antifolate drugs
A
A. Chloramphenicol:
- Mechanism of action
- Spectrum
- Resistance
- Indications
- Pharmacokinetics
- Side effects
B. Polymixins:
- Features
- Polymixin B
- Polymixin E
C. Antifolate drugs:
-
Sufonamides:
- Types
- Oral absorbable:
- Medium-acting
- Sulfamethoxazole
- Sulfadiazine
- Long-acting
- Sulfadoxine
- Medium-acting
- Oral non-absorbable
- Sulfasalazine
- Topical
- Sulfacetime
- Silver sulfadiazine
- Sulfadimidine
- Oral absorbable:
- Mechanism of action
- Spectrum
- Resistance
- Pharmacokinetics
- Adverse effects
- Types
-
Trimethoprim
- Mechanism of action
- Spectrum
- Pharmacokinetics
-
Sulfamethoxazole + trimethoprim
- Spectrum
- Clinical use
- Contraindications
- Sulfadiazine + pyramethamine
12
Q
- Tetracyclines and glycylcyclines
A
A. Tetracyclines:
- Mechanism of action
- Drugs (comparison)
- Short-acting
- Tetracycline
- Oxytetracycline
- Long-acting
- Doxycycline
- Minocycline
- Lymecycline
- Short-acting
- Pharmacokinetics
- Absorption
- Distribution
- Elimination
- Spectrum/clinical use
- Resistance
- Side effects
- Drug interactions
B. Glycylcyclines:
- Drugs
- Tigecycline
- Mechanism of action
- Spectrum
- Pharmacokinetics
- Indications
- Adverse effects
13
Q
- Aminoglycosides
A
- Mechanism of action
- Spectrum
- Main indications
- Monotherapy
- Combination therapy
- Pharmacokinetics
- Administration
- Drugs
- Neomycin
- Streptomycin
- Gentamycin
- Tobramycin
- Kanamicin
- Amikacin
- Netilmycin
- Spectinomycin
- Adverse effects
14
Q
- Quinolones and fluoroquinolones
A
- Mechanism of action
A. Non-fluorinated quinolones:
- Drug
- Nalidixic acid
- Pharmacokinetics
- Spectrum
- Resistance
- Indications
- Adverse effects
B. Fluoroquinolones:
- Comparison to non-fluorinated quinolones
- Pharmacokinetics (2-4 gens)
- Clinical use
- Adverse effects
-
1st generation
- Drug
- Norfloxacin
- Spectrum
- Pharmacokinetics
- Clinical use
- Adverse effects
- Drug
-
2nd generation
-
Drugs
- Cirpofloxacin
- Ofloxacin
- Spectrum
- Pharmacokinetics
- Clinical use
- Adverse effects
-
Drugs
-
3rd generation
- Drug
- Levofloxacin
- Sepctrum
- Pharmacokinetics
- Clinical uses
- Adverse effects
- Drug
-
4th generation
- Drugs
- Moxifloxacin
- Prulifloxacin
- Spectrum
- Pharmacokinetics
- Adverse effects
- Drugs
15
Q
- Macrolides. Ketolides
A
A. Macrolides:
- Drugs
- Mechanism of action
- Spectrum
- Resistance
- Clinical uses
- Pharmacokinetics
- Side effects
B. Ketolides:
-
Telithromycin
- Spectrum
- Clinical use
- Pharmacokinetics
- Adverse effects